Unprecedented breakthroughs have been made in cancer immunotherapy in recent years.
Particularly immune checkpoint inhibitors have fostered hope for patients with cancer …

Simple Summary Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of
all lung cancers, and the postoperative survival of early-stage NSCLC patients remains …

Cuproptosis, a newly identified form of programmed cell death, plays vital roles in
tumorigenesis. However, the interconnectivity of cuproptosis and ferroptosis is poorly …

Oral squamous cell carcinoma (OSCC) escape from the immune system is mediated through
several immunosuppressive phenotypes that are critical to the initiation and progression of …

Background Tumor immune microenvironment (TIME) and cancer antigen expression, key
factors for the development of immunotherapies, are usually based on the data from primary …

Aims We investigated the clinical implications and molecular features of TLS in stage I lung
adenocarcinoma (LUAD). Methods We retrospectively reviewed the clinicopathological …

Abstract Background Circular RNAs (circRNAs) have been shown to mediate tumor‐
associated macrophages (TAMs) to regulate the development of many cancers, including …

Chimeric antigen receptor (CAR) T-cell therapy has achieved potent antitumor efficacy in
hematological malignancies; however, because of limitations in CAR T-cell recruitment …

Background CD39, a rate-limiting enzyme to convert extracellular ATP (eATP) to adenosine,
has been reported to be a key modulator of immune response, but its correlation with …

Objective Lung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its
immune infiltration features are not comprehensively understood. To address the issue, the …